MTOR and hepatocellular carcinoma: Even though rapamycin, an inhibitor of mTOR, effectively reduces HCC with mTOR activation [18], long-term usage of rapamycin in a HCC mouse model causes liver injury, inflammation and subsequently higher tumor burden [20].